Amphastar Pharmaceuticals, Inc. (AMPH) Secures FDA Approval for Generic Iron Sucrose Injection

We recently compiled a list of the 11 Best Pharma Stocks to Invest in for the Long Term. Amphastar Pharmaceuticals, Inc. stands eighth among them.

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH), a California-based company specializing in complex generics and proprietary medicines, is strengthening its position in the pharmaceutical market with major manufacturing and product expansion initiatives.

A centerpiece of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)’s recent strategy is its plan to quadruple U.S. manufacturing capacity at its Rancho Cucamonga headquarters over the next few years. The project includes building a new state-of-the-art production plant with advanced automation and technology integration. By making all finished products domestically, the business aims to reduce reliance on global supply chains while creating new jobs in research, engineering, and manufacturing.

On the product side, the corporation recently secured FDA approval for its generic Iron Sucrose Injection, a bioequivalent to Venofer, with a Q3 2025 launch targeting the $513 million U.S. market for iron deficiency anemia. Its pipeline includes four additional ANDAs, a biosimilar insulin candidate, and an exclusive licensing deal with Nanjing Anji Biotechnology for three novel proprietary peptides. These assets, which include candidates for cancer, novel taxane therapies, and retinal disease, reflect the company’s push into innovative and high-value treatments, solidifying its position among the best pharmaceutical stocks to watch.

Amphastar Pharmaceuticals, Inc. (AMPH) Secures FDA Approval for Generic Iron Sucrose Injection

Commercial momentum is also being driven by BAQSIMI, Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)’s glucagon nasal powder for severe hypoglycemia, which recorded a 51% sales increase in the most recent quarter. The product’s strong performance highlights the company’s ability to successfully commercialize therapies that address urgent and chronic patient needs.

While we acknowledge the risk and potential of AMPH as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than AMPH and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure. None.